145 related articles for article (PubMed ID: 9777791)
21. Tazarotene in combination with topical corticosteroids.
Lebwohl M; Poulin Y
J Am Acad Dermatol; 1998 Oct; 39(4 Pt 2):S139-43. PubMed ID: 9777792
[TBL] [Abstract][Full Text] [Related]
22. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study.
Shalita AR; Chalker DK; Griffith RF; Herbert AA; Hickman JG; Maloney JM; Miller BH; Tschen EH; Chandraratna RA; Gibson JR; Lew-Kaya DA; Lue JC; Sefton J
Cutis; 1999 Jun; 63(6):349-54. PubMed ID: 10388959
[TBL] [Abstract][Full Text] [Related]
23. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study.
Rigopoulos D; Gregoriou S; Katsambas A
Acta Derm Venereol; 2007; 87(2):167-8. PubMed ID: 17340027
[No Abstract] [Full Text] [Related]
24. Pharmacologic profile of tazarotene.
Duvic M
Cutis; 1998 Feb; 61(2 Suppl):22-6. PubMed ID: 9787988
[TBL] [Abstract][Full Text] [Related]
25. Periungual pyogenic granulomas due to topical tazarotene for nail psoriasis.
Piraccini BM; Venturi M; Patrizi A
G Ital Dermatol Venereol; 2014 Jun; 149(3):363-6. PubMed ID: 24819765
[TBL] [Abstract][Full Text] [Related]
26. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect.
Weinstein GD; Krueger GG; Lowe NJ; Duvic M; Friedman DJ; Jegasothy BV; Jorizzo JL; Shmunes E; Tschen EH; Lew-Kaya DA; Lue JC; Sefton J; Gibson JR; Chandraratna RA
J Am Acad Dermatol; 1997 Jul; 37(1):85-92. PubMed ID: 9216528
[TBL] [Abstract][Full Text] [Related]
27. Tazarotene gel: efficacy and safety in plaque psoriasis.
Weinstein GD
J Am Acad Dermatol; 1997 Aug; 37(2 Pt 3):S33-8. PubMed ID: 9270554
[TBL] [Abstract][Full Text] [Related]
28. Topical tazarotene: a review of its use in the treatment of plaque psoriasis.
Dando TM; Wellington K
Am J Clin Dermatol; 2005; 6(4):255-72. PubMed ID: 16060713
[TBL] [Abstract][Full Text] [Related]
29. Short contact therapy with tazarotene in psoriasis vulgaris.
Veraldi S; Caputo R; Pacifico A; Peris K; Soda R; Chimenti S
Dermatology; 2006; 212(3):235-7. PubMed ID: 16549919
[TBL] [Abstract][Full Text] [Related]
30. Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive.
Yu Z; Yu D; Walker PS; Tang-Liu DD
Clin Pharmacokinet; 2004; 43(10):673-84. PubMed ID: 15244497
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous determination of tazarotene and its active metabolite tazarotenic acid in minipig plasma by LC-MS/MS and its application in pharmacokinetic study after topical administration of tazarotene gel.
Tong Y; Pan H; Sun C; Xin X; Ding L; Ma P
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jan; 978-979():173-8. PubMed ID: 25550192
[TBL] [Abstract][Full Text] [Related]
32. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
33. Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis.
Weinstein GD
Br J Dermatol; 1996 Oct; 135 Suppl 49():32-6. PubMed ID: 9035703
[TBL] [Abstract][Full Text] [Related]
34. Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy.
Tanghetti E; Lebwohl M; Stein Gold L
J Drugs Dermatol; 2018 Dec; 17(12):1280-1287. PubMed ID: 30586259
[TBL] [Abstract][Full Text] [Related]
35. Topical tazarotene therapy for psoriasis, acne vulgaris, and photoaging.
Guenther LC
Skin Therapy Lett; 2002 Mar; 7(3):1-4. PubMed ID: 12007011
[TBL] [Abstract][Full Text] [Related]
36. Treatment of keratoderma blennorrhagicum with tazarotene gel 0.1%.
Lewis A; Nigro M; Rosen T
J Am Acad Dermatol; 2000 Aug; 43(2 Pt 2):400-2. PubMed ID: 10901734
[TBL] [Abstract][Full Text] [Related]
37. A phase 1 study of tazarotene in adults with advanced cancer.
Jones PH; Burnett RD; Fainaru I; Nadolny P; Walker P; Yu Z; Tang-Liu D; Ganesan TS; Talbot DC; Harris AL; Rustin GJ
Br J Cancer; 2003 Sep; 89(5):808-15. PubMed ID: 12942109
[TBL] [Abstract][Full Text] [Related]
38. Future trends: a new generation of retinoids.
Chandraratna RA
J Am Acad Dermatol; 1998 Oct; 39(4 Pt 2):S149-52. PubMed ID: 9777794
[TBL] [Abstract][Full Text] [Related]
39. Receptor-selective retinoids for psoriasis: focus on tazarotene.
Weindl G; Roeder A; Schäfer-Korting M; Schaller M; Korting HC
Am J Clin Dermatol; 2006; 7(2):85-97. PubMed ID: 16605289
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
Gold LS; Lebwohl MG; Sugarman JL; Pariser DM; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
J Am Acad Dermatol; 2018 Aug; 79(2):287-293. PubMed ID: 29614243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
